TAGAMET HB 200
LOE ApproachingNDAORALSUSPENSION
Approved
Jul 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGAMET HB 200 is an oral suspension small-molecule formulation approved in 1999. The generic name and mechanism of action are not publicly disclosed in available data. This product is approaching loss of exclusivity.
LOE Approaching
With LOE approaching and 30% competitive pressure, the brand team is likely rightsizing; this is a defensive maintenance position rather than growth opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TAGAMET HB 200 currently has zero linked job openings, reflecting its LOE-approaching status and declining commercial focus. Careers on this product are defensive and transition-oriented, better suited to professionals managing mature brands or preparing for generic competition than to those seeking growth roles.
Brand Manager (Maintenance)Product Manager
Worked on TAGAMET HB 200 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.